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Background: Survivors of combat trauma can have long and challenging recoveries, which may be complicated by
infection. Invasive fungal infections are a rare but serious complication with limited treatment options. Currently,
aggressive surgical debridement is the standard of care, with antifungal agents used adjunctively with uncertain
efficacy. Anecdotal evidence suggests that antifungal agents may be ineffective in the absence of surgical
debridement, and studies have yet to correlate antifungal concentrations in plasma and wounds.
Case presentation: Here we report the systemic pharmacokinetics and wound effluent antifungal concentrations
of five wounds from two male patients, aged 28 and 30 years old who sustained combat-related blast injuries in
southern Afghanistan, with proven or possible invasive fungal infection. Our data demonstrate that while voriconazole
sufficiently penetrated the wound resulting in detectable effluent levels, free amphotericin B (unbound to plasma) was
not present in wound effluent despite sufficient concentrations in circulating plasma. In addition, considerable
between-patient and within-patient variability was observed in antifungal pharmacokinetic parameters.
Conclusion: These data highlight the need for further studies evaluating wound penetration of commonly used
antifungals and the role for therapeutic drug monitoring in providing optimal care for critically ill and injured war
fighters.
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A significant number of combat-related casualties have re-
sulted from the ongoing military operations in Iraq and
Afghanistan [1]. Improvements in tactical combat casualty
care have led to increased survival rates [2,3], resulting in
prolonged survival of critically ill and injured patients who
experience complex treatment courses, often with compli-
cations. Invasive fungal infection is a major complication
that affects patients regardless of immune status [4], with
reported risk factors including injury while serving in
riparian environments of southern Afghanistan [5], dis-
mounted blast injury resulting in polytrauma (severe* Correspondence: kevin.s.akers.mil@mail.mil
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unless otherwise stated.lower extremity and groin trauma from stepping on an
improvised explosive device), and massive blood transfu-
sion [6]. Inoculation of soil-dwelling molds into wounds is
proposed to occur at the time of injury, with subsequent
growth of vegetative mold structures within human tissue.
Fittingly, invasive fungal infection has been recently docu-
mented in patients that sustained wounds contaminated
with wood, soil, and gravel following a major tornado [7].
Diagnosis is often delayed by the need for specimen col-
lection, limited microbiological assays in austere field hos-
pitals, histopathological confirmation, and positive fungal
culture. Thus, the median time from infection to diagnosis
is 10 days [6]. Treatment is primarily surgical debride-
ment, as the efficacy of antifungal agents remains unclear
[8,9]. In clinical practice, antifungal agents are anecdotally
observed to be ineffective in halting the progression of in-
vasive infection despite what is perceived to be adequatehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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into clinically viable tissue are often necessary, resulting in
severely disabling procedures such as extremity amputa-
tion, hip disarticulation, or even hemipelvectomy.
In lieu of antifungal therapies sufficiently potent as to
eliminate the burden of life-saving but disabling surger-
ies, optimizing the dose of currently available antifungal
agents might help maximize clinical recovery while limit-
ing toxic side effects. Furthermore, little is known about
tissue penetration of antimicrobials, including antifun-
gals, and whether plasma concentrations are correlated
to wound penetration. Negative pressure wound therapy
(NPWT), frequently used in the care of wound infections,
affords an opportunity to collect wound effluent for evalu-
ation. Previous studies have examined wound effluent
for the presence of bacteria [10], inflammatory cytokines
[11-15], and other protein components [16] but the pres-
ence of antimicrobials in wound effluent has not been ex-
amined. To gain insight into the penetration of clinically
useful antimicrobial agents across wounds under nega-
tive pressure, we undertook two prospective observational
studies of antimicrobials, including antifungals, in patients
with trauma-related wounds. Here we report the systemic
pharmacokinetics (PK) and effluent antifungal concentra-
tions of five wounds in two blast-injured combat casualties
with proven or possible invasive fungal infection.
Case presentation
This study was conducted under a protocol reviewed and
approved by the U.S. Army Medical Research and Materiel
Command Institutional Review Board and in accordance
with approved protocols BAMC C.2013.095 and H-09-059.
Two patients receiving antifungal therapy for proven or
possible invasive mold infection were enrolled with in-
formed consent into institutional review board-approved
observational pharmacokinetic (PK) studies examining the
adequacy of antimicrobial dosing in critically ill patients,
or in the context of military wound infections. At the time
of initial PK steady-state sampling, both patients were
receiving liposomal amphotericin B (L-AmB) with one
also receiving voriconazole at recommended mainten-
ance doses (5 mg/kg and 4 mg/kg, respectively). Periph-
eral blood samples were obtained at time points spanning
the dose interval for each agent. Simultaneously, wound
effluent was collected over 24 hours (the dose interval for
L-AmB) from available sites treated with NPWT (Wound
V.A.C., KCI, San Antonio, TX) into canisters lacking
the congealing agent. Wound effluent was recovered from
canisters by syringe aspiration for volumetric measure-
ment and determination of antifungal concentration.
Total and free concentrations of amphotericin B and
voriconazole were determined in plasma and wound ef-
fluent using high-performance liquid chromatography
(HPLC). Data was collected on a Dionex UltiMate 3000instrument (ThermoFisher, Waltham, MA) equipped with
an HPG 3400SD binary pump, WPS autosampler, and
DAD-3000 UV-visible detector. For amphotericin B,
analysis was conducted as previously described [17]
with slight modifications. The mobile phase consisted
of 10 mM acetate buffer (pH 4.0) and acetonitrile, de-
livered isocratically at a 63:37 ratio and a flow rate of
0.6 mL/min [17]. The stationary phase was a Phenomenex
Luna C18(2) 150x4.6 mm column (100 Å pore size, 5 μm
particle size) preceded by a 10 mm guard column with
matching chemistry. Seven calibration standards, 150 μL
each, were prepared containing 0.1-200 μg/mL amphoteri-
cin B on a free drug basis (deoxycholate, Sigma, St. Louis,
MO) and 50 μL of 25 μg/mL natamycin as an internal
standard to correct for losses during sample preparation.
One mL of acetonitrile:acetic acid (9:1) was added to each
sample, which was then vortexed briefly and stored at
room temperature in darkness for 1 hour. Each sample
was centrifuged at 10,000 × g for 10 min to precipitate
protein from the sample, after which the supernatant was
loaded onto the HPLC. Detection was by UV at 405 nm
for amphotericin B and 303 nm for natamycin. Injection
volume was 50 μL. Retention times were 10 min for
amphotericin B and 4.5 min for natamycin. The calibra-
tion curve was constructed using the peak area ratio of
the analyte (amphotericin B) and the internal standard
(natamycin). To determine total drug levels in patient
samples, 50 μL of 25 μg/mL natamycin was added to
150 μL of plasma or effluent and the same preparation
and analysis procedures were followed.
Voriconazole was identified by HPLC as previously de-
scribed [18,19]. The mobile phase consisted of 10 mM
phosphate buffer (pH 7.0) and acetonitrile, delivered in a
gradient (20-50% acetonitrile over 10 minutes) at a flow
rate of 1 mL/min. The stationary phase was a Phenomenex
Luna Phenyl-Hexyl 150x4.6 mm column (100 Å pore size,
5 μm particle size) column preceded by a 10 mm guard
column with matching chemistry. Six calibration stan-
dards were prepared containing 1–50 μg/mL voricona-
zole (SelleckChem, Houston, TX) and 1 μL of 50 μg/mL
itraconazole as an internal standard to correct for losses
during sample preparation. Sample cleanup was accom-
plished by protein precipitation with 400 μL methanol
followed by centrifugation at 10,000 × g for 10 min. The
supernatant was dried under air (15–20 L/min) and
reconstituted in 200 μL MeOH:phosphate buffer (1:1).
Detection was by UV at 260 nm for both voriconazole
and itraconazole. Injection volume was 25 μL. Reten-
tion times were 3.6 min for voriconazole and 9.8 min
for itraconazole. To determine total drug levels in patient
samples, 1 μL of itraconazole (50 μg/mL in methanol)
was added to 200 μL of each plasma or effluent sample
and the same preparation and analysis procedures were
followed.
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and effluent were determined using ultrafiltration units
as previously described [20-22]. Briefly, 300 μL of plasma
or effluent was loaded into each cartridge and samples
were centrifuged at 1,500 × g for 30 min. The filtrate was
assayed by HPLC as described above and the results were
volume-corrected to find the concentration of unbound
drug for each sample.
From the resulting plasma time-concentration curves,
PK parameter estimates were determined by non-
compartmental analysis using standard WinNonLin v6.3
(Pharsight Inc., Sunnyvale, CA). The adequacy of antifungal
concentrations in wound effluent to suppress mold infec-
tions were interpreted using minimum inhibitory concen-
trations (MICs) of 0.5 μg/mL for amphotericin B against
Mucorales molds and 1.0 μg/mL for voriconazole against
Aspergillus spp. [23,24], the lowest concentrations at which
growth of these organisms are reliably inhibited in vitro.
Potential drug interactions were evaluated using the Lexi-
Interact™ Online software (Lexicomp, Inc., Hudson, OH).
Patient 1
A 30 year-old male suffered a complex blast injury as a
result of a dismounted improvised explosive device blast
in southern Afghanistan, resulting in polytrauma includ-
ing bilateral above-the-knee amputations, perineal/gluteal
avulsion and 20% total body surface area burns to the pos-
terior thighs and back. Initial resuscitation and damage
control surgery was performed in Afghanistan, followed
by medical evacuation on post-injury day 3 to Landstuhl
Regional Medical Center (LRMC) in Germany. At LRMC,
tissue samples of the lower extremity amputation sites
and gluteal wounds were collected as part of clinical care
for early detection of invasive fungal infection in accord-
ance with the LRMC “blast protocol” [8], demonstrating
angioinvasive non-septate branching hyphae diagnostic of
a proven invasive fungal infection by a Mucorales mold
[9]. Repeated surgical debridements performed at the
discretion of the clinical care team with tissue fungal
cultures (post-injury days 3 to 7) resulted in recovery of
Aspergillus flavus, A. terreus, Fusarium sp. and an un-
identified Mucorales mold. Following transfer to Brooke
Army Medical Center, subsequent tissue fungal cultures
from debridements recovered Saksenea erythrospora on
10 different occasions between post-injury days 12 and 46,
with non-septate branching hyphae observed but not
cultured on 5 additional soft tissue specimens collected
on 3 separate days. Additionally, Fusarium sp. was re-
covered on post-injury day 59. Plasma and effluent sam-
pling was performed on post-injury day 18 (Patient 1,
Table 1, antifungal treatment day 15) following a once-
daily dose of L-AmB (5 mg/kg IV), with effluent recovered
from two abdominal NPWT sites (midline and left lower
quadrant, Figure 1). While the plasma peak and troughconcentrations were 25.5 μg/mL and 6.1 μg/mL, respect-
ively (Table 1), total amphotericin B in the wound effluent
was 0.2-0.3 μg/mL and free amphotericin B levels were
undetectable by our assay (Table 2). At the time of sam-
pling, NPWT with periodic instillation of Dakin’s solution
was employed to provide local antifungal therapy to the
subject’s bilateral lower extremity amputation sites, pre-
cluding effluent collection at these locations. Patient 1 sur-
vived to hospital discharge on post-injury day 193.
Patient 2
A 28 year-old male was injured by a close-proximity blast
from a rocket-propelled grenade, causing multiple pene-
trating shrapnel injuries to the chest and abdomen (includ-
ing liver and duodenal lacerations), as well as fractures of
the humerus and calcaneus. Following wound debride-
ments and exploratory laparotomy with distal gastrec-
tomy, duodenectomy, and abdominal fascia closure,
NPWT devices were applied over surgical sites on the
arm, abdomen, and heel. During routine wound de-
bridements, Aspergillus flavus was cultured from soft
tissues of the hip and posterior thigh on post-injury
days 10, 13 and 14. On post-injury day 10, histopath-
ology identified fungal elements in viable skeletal muscle
tissue from the groin, and in non-viable connective tissues
of the foot as well as non-viable serosal adhesions of the
antrum of the stomach and first part of the duodenum.
On post-injury day 21, fungal elements were observed
again in necrotic tissues of the groin. No angioinvasion
was observed, thus establishing the diagnosis as probable
invasive fungal infection [9]. Plasma and wound effluent
were sampled on post-injury day 15 (Patient 2a, Table 1,
antifungal treatment day 4) following doses of L-AmB
(5 mg/kg IV every 24 h) and voriconazole (4 mg/kg IV
every 12 h). Concurrent medications potentially inter-
fering with voriconazole metabolism given on this date
included pantoprazole 40 mg IV every 12 h and quetia-
pine 25 mg PO every 24 h. Despite apparently adequate
plasma levels of amphotericin B (trough 12.8 μg/mL,
Figure 1) and voriconazole (trough 3.0 μg/mL, Figure 2),
free concentrations of amphotericin B (unbound to pro-
tein) in wound effluent were below the limit of detection
for the assay (<2.5 ng/mL, Table 2) and thus presumed
to be sub-inhibitory for Mucorales (MIC ≤0.5 μg/mL).
Whereas free voriconazole was detected at 2.7 μg/mL
and 1.6 μg/mL from the arm and abdominal sites, respect-
ively, the concentration in calcaneus effluent (0.6 μg/mL)
was presumed to be sub inhibitory (MIC ≤1.0 μg/mL). In
patient 2, plasma PK sampling was again performed for
voriconazole only on post-injury day 21 (Patient 2b,
Table 1, treatment day 11, and 7 days after the initial
PK sampling). Concurrent medications potentially interfer-
ing with voriconazole metabolism given on this date in-
cluded pantoprazole 40 mg IV every 12 h and ciprofloxacin
Table 1 Patient characteristics and pharmacokinetic
values
Patient 1 2a 2b
Post-Injury Day 18 15 21
Treatment Day 15 4 11
Age (years) 30 28 28
Weight (kg) 78.8 77.1 60.1
Antifungal L-AmB L-AmB Voriconazole Voriconazole
Dose (mg) 400 400 320 320
Dose (mg/kg) 5.1 (24 h) 5.2 (24 h) 4.2 (12 h) 5.3 (12 h)
Peak (μg/mL) 25.5 58.4 10.4 3.5
Trough (μg/mL) 6.1 12.8 3.0 0.7
AUCτ(μg · h/mL) 262.5 534.7 67.5 24.1
T1/2 (h) 23.3 16.3 7.6 3.2
Vd (L/kg) 0.52 0.21 0.58 1.28
Clearance
(mL/kg/min)
0.32 0.16 1.02 3.69
Plasma % bound 100% 100% 32.7 ± 8.2 22.1 ± 4.1%
Effluent % bound 55.6% (RUE) N/A
100% 100% 75.0% (abd.)




AST/ALT (IU/L) 193/59 211/318 61/72
INR 1.4 1.4 1.2
Dose interval: 24 hours for L-AmB, 12 hours for voriconazole. Abd, abdomen;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; calc, calcaneus;
eGFR, estimated glomerular filtration rate; INR, international normalized ratio;
RUE, right upper extremity; T1/2, half-life; Vd, volume of distribution.
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of voriconazole increased nearly three-fold while the
weight-adjusted volume of distribution more than dou-
bled (Table 1). This likely reflected improvement in hepatic
function indicated by decreasing aspartate aminotransfer-
ase and alanine transaminase values, as well as discontinu-
ation of quetiapine 6 days previously. Pantoprazole was
continued at the same dose and frequency at both sam-
pling periods. These changes resulted in a significantlyFigure 1 Amphotericin B concentrations in plasma and wound effluent inreduced 12-hour area under the curve (AUC), a meas-
ure of overall voriconazole exposure, and much lower
peak and subtherapeutic trough concentrations. These
changes occurred despite an increased mg/kg dose of
voriconazole, which in turn resulted from catabolic loss
of 17 kg over 1 week caused by limiting feeding in the
setting of penetrating gastrointestinal trauma. Patient 2
survived to hospital discharge on post-injury day 99.
Conclusions
Invasive fungal infection is a complication of combat injur-
ies, particularly those sustained in southern Afghanistan,
with risk factors of dismounted complex blast injury and
high blood transfusion requirements during trauma resus-
citation [6,25]. Necrotizing soft-tissue infections following
natural disasters, such as tornados, have also been docu-
mented recently [7]. In an effort to optimize the care of
severely injured and critically ill patients with fungal in-
fections, we measured antifungal concentrations in the
plasma of two patients. In addition, we determined an-
tifungal concentrations in wound effluent to infer the
passage of antifungal agent through and across the
wounds under negative pressure. Interestingly, free concen-
trations of amphotericin (according to theory, the fraction
available to exert antifungal activity) were undetectable in
the wound effluent captured from all five sites in two pa-
tients with high concurrent plasma concentrations. In one
of the patients, free voriconazole was found at con-
centrations likely sufficient to inhibit molds with an
MIC ≤1.0 μg/mL in the effluent of two sites. However,
concentrations were likely sub-inhibitory in effluent
from a wound overlying the calcaneus, a site known to be
challenging for adequate drug penetration due to its lim-
ited blood flow [26]. Consistent with the treatment of inva-
sive fungal infection in immunocompromised populations,
surgical debridement has been the primary therapy, with
antifungal medications playing an adjunctive role. This is
highlighted by the observation that Patient 1 recovered
without receiving voriconazole despite the occurrence of
Aspergillus terreus, a species with intrinsically reduced sus-
ceptibility to amphotericin B.two patients with 5 wounds. Abd, abdomen; LLQ, left lower quadrant.
Table 2 Effluent antifungal concentration and negative-pressure wound therapy parameters
Amphotericin B (μg/mL) Voriconazole (μg/mL)
Patient Site Pressure (mmHg) Effluent (mL) Total Free Total Free
1 Abd −125 14 0.3 <LOD – –
LLQ −125 37 0.2 <LOD – –
2a Arm −125 96 3.0 ± 0.4 <LOD 2.7 ± 0.2 1.5 ± 0.002
Abd −125 60 1.3 ± 0.1 <LOD 1.6 ± 0.2 1.2 ± 0.01
Heel −125 28 1.3 ± 0.1 <LOD 0.6 ± 0.1 0.6 ± 0.01
LOD, limit of detection (2.5 ng/mL). Abd, abdomen; LLQ, left lower quadrant; LOD, limit of detection.
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ters for L-AmB between the two patients who had a nearly
2-fold increase in the AUC despite identical age and body
weight, notwithstanding bilateral lower extremity am-
putations in Subject 1 (the impact of amputations on
systemic PK is undefined). This PK variability may re-
flect differences in renal excretion as Subject 1 had renal
insufficiency at the time of sampling (Table 1). Likewise,
the two patients may have had non-quantifiable differ-
ences in their capacity for hepatic metabolism of L-AmB
given their differential elevation in aminotransferase
levels (Table 1) [27]. Patient 2 demonstrated significantly
increased voriconazole clearance between treatment days
4 and 11, as demonstrated by trough concentrations of 3.0
and 0.7 μg/mL, respectively. This may reflect, in part,
improvements in his capacity for hepatic metabolism
through the 2C19, 3A4 and 2C9 cytochrome P450 (CYP)
enzymes, which constitute the major metabolic pathways
for voriconazole [28,29]. A changing landscape of drug
interactions may also have contributed, as quetiapine is
a major substrate for CYP3A4 and minor substrate for
CYP2D6, which are both minor metabolic pathways for
voriconazole. Pantoprazole, an inhibitor of the enzyme pri-
marily responsible for voriconazole metabolism (CYP2C19),
was continued at the same dose during both sampling
episodes, and thus was unlikely to be the sole contribu-
tor to the changes in voriconazole exposure. Ciprofloxacin
is a weak inhibitor of CYP3A4, a minor metabolic pathway
for voriconazole.Figure 2 Voriconazole concentrations for Patient 2 in plasma and wound e
11 (2b). Abd, abdomen.These PK parameter changes developed despite an
increase in his mg/kg dose, attributable to significant
weight loss while continuing to receive a fixed dose of
voriconazole. Had the effluent been sampled again on
treatment day 11, subtherapeutic voriconazole concen-
trations would likely have been found despite his dose
exceeding the package-insert recommended dose of
4 mg/kg every 12 h. Furthermore, if this functional under-
dosing could have been detected via real-time therapeutic
drug monitoring, a dose increase suitable for his demon-
strated metabolic capacity could have been recommended.
This situation highlights the need for vigilance of patients’
daily weights, and the potential need for frequent adjust-
ments to medication dosages according to body weight,
which can fluctuate significantly in both directions and
for a variety of reasons in critically ill patients. Add-
itionally, the significant degree of between-patient and
within-patient PK variability we observed suggests that
individuals requiring antimicrobial therapy, particularly
for life-threatening infections, may benefit from real-time
pharmacokinetic monitoring to optimize efficacy and re-
duce toxicity [30]. Unfortunately such monitoring is not
clinically available for the majority of antimicrobial agents,
and advancements in technology are needed to determine
drug concentrations in real-time, ideally at or near the
point of care.
This study has inherent limitations. Only two patients
with 5 wounds were studied, reflecting limitations in
the available patient population at our facility. Inffluent on treatment day 4 (2a), and in plasma only on treatment day
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the histopathologically proven site of invasive fungal
infection at the extremity amputation sites. Our con-
clusion that free amphotericin B levels were inadequate in
the wound is based upon levels of protein binding in the
wound effluent, outside the actual wound tissue, and we
acknowledge that the degree of protein binding in effluent
may not accurately reflect what is occurring in the wound
tissue itself. However, free voriconazole was detectable in
wound effluent, as we have also observed for numerous
conventional antibacterial agents (unpublished data), and
wound effluent cytokine analyses are currently being used
to direct clinical care [31]. Our concern is also predicated
on the canonical theory that the protein-bound fraction of
an antimicrobial is inert against microorganisms [32]. Our
investigation of effluent levels to reflect wound penetra-
tion is based upon practical limitations stemming from
the requirement for an FDA Investigational Device Ex-
emption to sample interstitial fluid concentrations using
tissue microdialysis (the only such catheter currently
approved by the FDA for human use is indicated for
intracranial placement). Finally, although multiple fungal
species were reported in the clinical record, neither anti-
fungal MICs nor the isolates were available to confirm
pathogen identity or antifungal susceptibility.
This preliminary report raises concern for the limited
passage of unbound amphotericin B across wounds in
combat casualties with proven or probable wound infec-
tions. These initial data require corroboration across lar-
ger data sets to ensure their clinical validity. Preclinical
models and broader human sampling may prove useful to
further characterize the penetration of currently available
antifungal agents across infected tissues of combat wounds.
Additionally, the PK changes we observed between patients
and dynamic changes within one patient demonstrate a
need for PK monitoring to optimize care for infections. In-
sights gained from such studies may lead to strategies to
improve the efficacy of antifungals against invasive fungal
infections.
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